Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,558

Document Document Title
WO/2018/001084A1
The present invention relates to the field of pharmaceutical chemistry. Disclosed are a heat shock protein inhibitor, and a manufacturing method and application thereof. The heat shock protein inhibitor has a characteristic structure rep...  
WO/2017/219083A1
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...  
WO/2017/223188A1
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.  
WO/2017/216705A1
The invention relates to a crystalline form of the (R)-4-(5- (cyclopropylethynyl)isoxazol-3-yl)-N-hydroxy-2-methyl-2- (methylsulfonyl)butanamide (i.e. the compound of formula (A)) with low hydroscopicity. The compound and compositions th...  
WO/2017/195216A1
The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and...  
WO/2017/193034A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/191000A1
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...  
WO/2017/193041A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/193063A1
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.  
WO/2017/187352A1
The invention relates to a new class of compounds of formula (I) targeting COX-1. The invention also relates to the use of some of such compounds as a tool to investigate the structure and function of the enzyme, in the treatment targeti...  
WO/2017/183723A1
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...  
WO/2017/176948A1
This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine- based chiral phase transfer catalysts. The invention also relates to novel quinine-based phase transf...  
WO/2017/165256A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2017/156009A1
In one aspect, the invention relates to a crystalline form of the structure: or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions co...  
WO/2017/153952A1
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. ...  
WO/2017/155844A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A -Y -L-R (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function o...  
WO/2017/151018A1
The invention relates to the chemistry of organic compounds, pharmacology and medicine, and pertains to the prevention and/or treatment of a state in mammals characterized by undesirable thrombosis, and, in particular, thromboses, thromb...  
WO/2017/147047A1
The present disclosure is directed to modulators of farnesoid X receptor. Methods of making and using these modulators is also described.  
WO/2017/147352A1
This invention relates to long-acting injectable compositions for combating parasites in animals, comprising at least one isoxazoline active agent, a liquid PEG and/or a neutral oil, optionally a co-solvent, and optionally a pharmaceutic...  
WO/2017/136727A3
The present disclosure relates generally to N-azepinyl-carboxamide derivatives and compositions, and their use as inhibitors of receptor-interacting protein kinase 1 which is a key regulator of inflammation, apoptosis and necroptosis.  
WO/2017/133521A1
Provided in the present invention is a compound represented by the following general formula (1), a pharmaceutically acceptable salt thereof, ester thereof or stereoisomer thereof. Also provided in the present invention also are a method...  
WO/2017/128896A1
Disclosed are an FXR agonist and a preparation method and use thereof, in particular relating to the compound having the structure of formula (I), a stereisomer or a pharmaceutically acceptable salt thereof. The series of compounds can b...  
WO/2017/131221A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...  
WO/2017/108927A1
The invention discloses polymorphic forms of Ingenol 3-(3,5-diethylisoxazole-4-carboxylate), and a process for preparation of the polymorphic forms.  
WO/2017/096484A1
This present disclosure relates to the use of a cranberry extract rich in proanthocyanidins as antibiotic synergizing agent to mitigate multidrug resistance and biofilm formation in different pathogenic bacteria. The synergistic combinat...  
WO/2017/096301A1
The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.  
WO/2017/089389A1
The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used in the treatment of Human African TRypanosomiasis.  
WO/2017/071411A1
A crystalline form of isoxadifen-ethyl of formula (I), the crystal preparation process, the analyses of the crystal through various analytical methods and using the crystal to prepare stable agrochemical formulation are provided. The use...  
WO/2017/069601A1
The present invention relates to novel aminoalkylazoles acting as inhibitors of malarial protease plasmepsin II. These can be used as medicines or as constituent of medicines for the treatment of malaria infection.  
WO/2017/070084A1
The disclosed subject matter provides N- hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using ...  
WO/2017/064512A1
Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preve...  
WO/2017/045751A1
The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as ASIC inhibitors.  
WO/2017/036404A1
Carboxy-substituted (hetero)aryl derivatives, pharmaceutical compositions comprising these compounds, and methods of preparing such compounds and compositions are provided. The compounds or compositions are useful in inhibiting xanthine ...  
WO/2017/039395A1
The present invention relates to a novel compound having an effect of inhibiting platelet aggregation and a salt thereof and, more specifically, to: a novel platelet aggregation inhibitor specifically inhibiting shear stress-induced plat...  
WO/2017/040564A1
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a periph...  
WO/2017/027309A1
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are def...  
WO/2017/027465A1
The invention relates to a process for preparing sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]is oxazol-5-yl)amino)benzoate.  
WO/2017/027312A1
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III); wherein R1c, R2C, R4C, Wc, Yc, Zc and Gc, are defined...  
WO/2017/027310A1
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula II.  
WO/2017/021246A1
This invention relates to a novel chemical process for the synthesis of N'-benzyl-5- methylisoxazole-3-carbohydrazide (Isocarboxazid) which comprises reacting 5-methyl-3- isoxazole carboxylic acid ester with benzylhydrazine or a salt the...  
WO/2017/019589A1
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The p...  
WO2017011371A1
The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins w...  
WO/2017/001926A8
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the trea...  
WO/2017/001926A3
Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting plasma kallikrein. Furthermore, the subject compounds and compositions are useful for the trea...  
WO/2016/210414A1
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...  
WO/2016/201096A1
The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of ot7-nAChR, and methods of preparing these compounds and compositions, ...  
WO/2016/193452A1
The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases.  
WO/2016/193459A1
The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases such as autoimmu...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/172424A1
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)  

Matches 1 - 50 out of 6,558